Search

everythinglearnresearchcommunity

for

Search:↓

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.

Scalp sunburns can cause permanent hair loss, so wearing UPF hats is essential. Tretinoin and Tacrolimus users should be cautious of increased photosensitivity and potential scalp issues.

Be skeptical of claims about new baldness cures; current treatments like finasteride, dutasteride, and minoxidil remain the best options. New products like Breezula and PP405 lack compelling evidence and may not be available soon.

The conversation discusses a hair loss and scalp care routine involving ciclopirox shampoo, benzoyl peroxide, clindamycin gel, clobetasol propionate, and calcipotriol to manage seborrheic dermatitis, folliculitis, and inflammation. It also touches on the role of diet and other treatments like oral minoxidil and pioglitazone for scalp health.

PP405, a potential treatment for male pattern baldness, shows promise with some participants experiencing hair regrowth in early trials. However, it is not yet considered a cure and may be used alongside existing treatments like minoxidil and finasteride.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

The user is using Minoxidil, finasteride, Nizoral, and dermarolling for hair loss but is not seeing results. They are considering trying a product called "capilia longa" for beard growth and are questioning its effectiveness.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

Peppermint Essential Oil (PEO) was discussed for its hair regrowth effects on shaved mice after 4 weeks. Specific treatments mentioned include Minoxidil (Min), Finasteride (Fin), and RU58841 (RU).

Eucapil is discussed as a potential hair loss treatment with some believing it to be effective, though its efficacy compared to finasteride is debated. It is considered an anti-androgen treatment, often used alongside other treatments like minoxidil and finasteride, but lacks independent studies to fully support its effectiveness.

A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

A user's humorous experience with using minoxidil to treat hair loss, which was met with laughter from other users.

Addressing hair loss by focusing on posture, blood flow, and craniofacial development. Methods include improving posture, cardiovascular activity, scalp massages, healthy diet, meditation, using minoxidil, and addressing craniofacial issues.

A user who has started to go bald and decided to try wearing a hair piece, discussing the experience of doing so and sharing tips for maintenance. The conversation includes discussion about confidence in relation to wearing a wig or hair piece, as well as advice on getting it cut and attached professionally.

The conversation discusses alternatives to minoxidil and finasteride for hair loss, with users expressing skepticism about the effectiveness of Redensyl, Procapil, and Baicapil. One user recommends Finax by Dr. Reddy as a reliable option in India.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Hair regrowth treatments are effective in mice but not yet available for humans. The discussion humorously highlights frustration over this disparity and mentions a project to genetically modify elephants to resemble mammoths.

PP405 is humorously suggested as a new hair loss cure with "shocking results." The conversation includes references to Minoxidil, finasteride, and RU58841.

Using a cap at night can prevent minoxidil from transferring to bedsheets and is safe for pets. Washing hair the next day is recommended for safety.

Piroctone olamine is more effective than ketoconazole for increasing hair growth and reducing itching and dandruff. Treatments discussed include Minoxidil, finasteride, and RU58841.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

Nizoral causes scalp and face itchiness and flakes. Piroctone olamine is suggested as an alternative.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.